Monday, July 12, 2010 8:56:04 AM
The important part of this for me was the current market for antibiotics for mastis. I have seen this 40-50 million number before. Of course the market ICCC is going for is sub-clinical mastis, which is potentially larger and has no treatment for.
New mastitis treatment may offer alternative to antibiotics
Agricultural Research, Feb, 2006 by Jan Suszkiw
A new weapon could be on tap for fighting bacteria that cause mastitis, an inflammatory udder disease of dairy cows costing around $2 billion annually in animal and milk-production losses.
In trials at ARS's Bovine Functional Genomics Laboratory, Beltsville, Maryland, scientists Max Paape and Douglas Bannerman showed that injecting the cows' mammary glands with the sugar Poly-x reduced mastitis infections at about one-twelfth the cost of antibiotics.
The sugar, a type known as a "polysaccharide," occurs naturally in the cell walls of certain yeasts. But when administered to nonlactating ("dry") dairy cows, the polysaccharide serves as a kind of biochemical bugle call that mobilizes the animals' immune system, especially to produce bacteria-killing 1 white blood cells.
"Previous work at Beltsville indicated that increasing the cell count in milk will prevent infection," says Paape, a dairy scientist. "Poly-x increases the cell count in dry-cow secretions for the first 5 days of the dry period, thus preventing infection by bacteria."
Today's mastitis-control programs often use several measures, like diagnostic testing, sanitation, herd separation, animal culling, teat dips, and antibiotic treatment. For conventional dairy operations, antibiotics use can be expensive, costing about $10 a cow, or $45 million nationwide, Paape estimates. The practice is also controversial, with concerns focusing on the potential for environmental contamination and the emergence of antibiotic-resistant bacteria.
Paape and Bannerman see some advantages to using Poly-x as a natural alternative--the lack of residues being one. Another is the expense. A tube of antibiotic costs around $2.50. By comparison, the ingredient cost for an experimental Poly-x treatment is only 20 cents.
http://findarticles.com/p/articles/mi_m3741/is_2_54/ai_n16069030/
Recent ICCC News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 06:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:32 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/16/2024 02:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:32 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 • GlobeNewswire Inc. • 01/08/2024 09:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 08:22:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:05:46 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 05:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:21 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 • GlobeNewswire Inc. • 10/05/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2023 04:25:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2023 06:49:33 PM
- ImmuCell Announces Submission of CMC Technical Section to the FDA • GlobeNewswire Inc. • 08/29/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:44 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 01:04:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/13/2023 06:28:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 08:05:21 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023 • GlobeNewswire Inc. • 07/11/2023 08:05:18 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM